奈达铂联合长春瑞滨治疗中晚期食管癌27例疗效分析 |
| |
引用本文: | 章海燕. 奈达铂联合长春瑞滨治疗中晚期食管癌27例疗效分析[J]. 现代保健, 2010, 0(32): 25-26 |
| |
作者姓名: | 章海燕 |
| |
作者单位: | 江苏省沐阳县人民医院,223600 |
| |
摘 要: | 目的 观察奈达铂联合长春瑞滨治疗中晚期食管癌的近期疗效与毒副反应.方法 对27例中晚期食管癌患者给予奈达铂80 mg/m2,第1天;长春瑞滨 25 mg/m2 ,第1天、第8天.每21 d为1个周期,至少应用2个周期.结果 CR(2/27)为5.5%,PR(13/27)为48.1%, SD(7/27)为25.5%,PD(5/27)为18.5%,有效率(RR)为55.5 %(15/27).主要毒副反应为骨髓抑制,表现为白细胞与血小板减少,以Ⅰ~Ⅲ度为主,Ⅲ~Ⅳ度骨髓抑制37.3%(10/27).结论 奈达铂联合长春瑞滨治疗中晚期食管癌疗效较好,毒副反应小,可临床推广.
|
关 键 词: | 奈达铂 长春瑞滨 中晚期食管癌 治疗 |
Effects of nedaplatin plus vinorelbine in treatment of middle and advanced esophageal cancer |
| |
Affiliation: | ZHANC Hal - yan. Shuyang People's Hospital, Shuyang 223600, China |
| |
Abstract: | Objective To evaluate efficacy and toxic reactions of nedaplatin plus vinorelbine in treatment of middle and advanced esophageal cancer. Methods 27 patients with esophageal cancer patients, nedaplatin 80 mg/m2, d1, vinorel- bine 25 mg/m2,dl and dS. Every 21 days for a cycle, at least two cycles. Results The overall response rate was 55.5 % (15/27) , with CR 5.5% (2/27) , PR 48.1% ( 13/27 ). SD 25.5% (7/27) and PD 18.5 % ( 5/27 ). The major toxicity was myelosuppression for white and thrombocytopenia, forⅠ-Ⅲ incidence degree. Ⅲ-Ⅳdegrees 37.3% (10/27). Conclusion Nedaplatin plus vinorelbine rather active in treating middle and advanced esophageal cancer with acceptable talerance, and it deserves further popularization. |
| |
Keywords: | Nedaplatin Vinorelbine Middle and advanced esophageal carcinoma Treatment |
本文献已被 维普 等数据库收录! |
|